Literature DB >> 9675742

Is screening for abdominal aortic aneurysm acceptable to the population? Selection and recruitment to hospital-based mass screening for abdominal aortic aneurysm.

J S Lindholt1, S Juul, E W Henneberg, H Fasting.   

Abstract

BACKGROUND: The aim of the study was to analyse whether the selection and recruitment for hospital-based mass screening for abdominal aortic aneurysms (AAA) is acceptable for the population according to the criteria from the Council of Europe.
METHODS: A random sample of 4404 65-73-year-old males were invited to hospital-based mass screening for AAA. As methods of secondary recruitment, they could change their time of appointment, and non-responders were reinvited once.
RESULTS: The attendance rate was 76 per cent; 4.2 per cent had AAA. Men with cardiopulmonary and vascular diseases had higher attendance rate (80.5 per cent), and prevalence of AAA (9.1 per cent). Men with potentially mobility-disabling diseases also had a higher attendance rate (80.4 per cent). However, possible unfavourable social selection was noticed in the group of retired men with no information of former occupation. They had 68.5 per cent attendance, and 7.6 per cent AAA. If true, this selection decreases the number of potentially diagnosed AAA by only 2 per cent. Opportunity of revised appointment and reinvitation of non-responders increased the primary attendance of 65 per cent to 76 per cent. More AAA were found at secondary scans (6.3 per cent compared with 3.9 per cent).
CONCLUSION: The attendance rate fell markedly with age, but the recruitment was high even at the age of 73, and travel distance and social class did not markedly influence uptake. A positive morbidity selection to screening for AAA was observed for cardiovascular or pulmonary diseases and potentially mobility-disabling diseases. Furthermore, higher prevalence of AAA was found for initial nonattenders. Thus, screening for AAA seems acceptable to the population, and extra efforts to increase the attendance are beneficial without increased costs per diagnosed AAA. Finally, if mass-screening proves to be cost-ineffective, selective screening of patients with hypertension or ischaemic heart disease might be beneficial.

Entities:  

Mesh:

Year:  1998        PMID: 9675742     DOI: 10.1093/oxfordjournals.pubmed.a024745

Source DB:  PubMed          Journal:  J Public Health Med        ISSN: 0957-4832


  7 in total

1.  Abdominal aortic aneurysm (AAA): cost-effectiveness of screening, surveillance of intermediate-sized AAA, and management of symptomatic AAA.

Authors:  Marc D Silverstein; Stephen R Pitts; Elliot L Chaikof; David J Ballard
Journal:  Proc (Bayl Univ Med Cent)       Date:  2005-10

2.  Office-based ultrasound screening for abdominal aortic aneurysm.

Authors:  Beau Blois
Journal:  Can Fam Physician       Date:  2012-03       Impact factor: 3.275

3.  Screening for abdominal aortic aneurysms: single centre randomised controlled trial.

Authors:  Jes S Lindholt; Svend Juul; Helge Fasting; Eskild W Henneberg
Journal:  BMJ       Date:  2005-03-09

4.  Ultrasound screening for abdominal aortic aneurysm: an evidence-based analysis.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2006-01-01

5.  Geography, private costs and uptake of screening for abdominal aortic aneurysm in a remote rural area.

Authors:  Sandra M Lindsay; John L Duncan; John Cairns; David J Godden
Journal:  BMC Public Health       Date:  2006-03-29       Impact factor: 3.295

6.  Prevalence and trends of the abdominal aortic aneurysms epidemic in general population--a meta-analysis.

Authors:  Xi Li; Ge Zhao; Jian Zhang; Zhiquan Duan; Shijie Xin
Journal:  PLoS One       Date:  2013-12-02       Impact factor: 3.240

7.  A population-based screening study for cardiovascular diseases and diabetes in Danish postmenopausal women: acceptability and prevalence.

Authors:  Marie Dahl; Lars Frost; Rikke Søgaard; Ib Christian Klausen; Vibeke Lorentzen; Jes Lindholt
Journal:  BMC Cardiovasc Disord       Date:  2018-02-05       Impact factor: 2.298

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.